[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing",
    "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $24.31, denoting a +1.17% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=8f2d8d23e156a20ebcc18f6f454fe60a74a837877d24db39b4d635469926f264",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750801505,
      "headline": "Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing",
      "id": 135512660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $24.31, denoting a +1.17% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=8f2d8d23e156a20ebcc18f6f454fe60a74a837877d24db39b4d635469926f264"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5174da6ecca3d83a662b5f7fa9f26f26caa1fda2aea22e74dc5a42722ae472f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750782960,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 135542455,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5174da6ecca3d83a662b5f7fa9f26f26caa1fda2aea22e74dc5a42722ae472f3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?",
    "summary": "PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.",
    "url": "https://finnhub.io/api/news?id=5c4f7360a1b1e638f10f9ab708d3565e404a83552a33b49e9cbfe943a62a8e22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750775100,
      "headline": "Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?",
      "id": 135506341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.",
      "url": "https://finnhub.io/api/news?id=5c4f7360a1b1e638f10f9ab708d3565e404a83552a33b49e9cbfe943a62a8e22"
    }
  },
  {
    "ts": null,
    "headline": "Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?",
    "summary": "ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.",
    "url": "https://finnhub.io/api/news?id=3ecf1da5251c6d2c303b3c305bef6437947dfff1c6835864825cb9fd2610054a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750767720,
      "headline": "Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?",
      "id": 135498818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.",
      "url": "https://finnhub.io/api/news?id=3ecf1da5251c6d2c303b3c305bef6437947dfff1c6835864825cb9fd2610054a"
    }
  },
  {
    "ts": null,
    "headline": "My 5 Favorite Dirt Cheap Stocks to Buy Right Now",
    "summary": "All of these factors -- particularly the import tariff announcements -- have weighed on investors' appetite for stocks.  Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) is the cheapest of the \"Magnificent Seven\" technology stocks that led market gains last year but tumbled this year amid concerns about tariffs and their impact on the economy.  It's the world's No. 1 search engine, and its presence in our daily routine and Alphabet's moves to use artificial intelligence (AI) to continually improve results should help it remain on top.",
    "url": "https://finnhub.io/api/news?id=143207b85e5591f0bf90712f33a5e52ad26d139fafb02f63f2727bed9af5218f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750763400,
      "headline": "My 5 Favorite Dirt Cheap Stocks to Buy Right Now",
      "id": 135501802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All of these factors -- particularly the import tariff announcements -- have weighed on investors' appetite for stocks.  Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) is the cheapest of the \"Magnificent Seven\" technology stocks that led market gains last year but tumbled this year amid concerns about tariffs and their impact on the economy.  It's the world's No. 1 search engine, and its presence in our daily routine and Alphabet's moves to use artificial intelligence (AI) to continually improve results should help it remain on top.",
      "url": "https://finnhub.io/api/news?id=143207b85e5591f0bf90712f33a5e52ad26d139fafb02f63f2727bed9af5218f"
    }
  },
  {
    "ts": null,
    "headline": "How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years",
    "summary": "How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years",
    "url": "https://finnhub.io/api/news?id=a195d6cf6f63ff3a582ba0781f7f880d2d995b0baa099181bc58ff07b3fec92f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750762800,
      "headline": "How To Build A $1,000,000 Dividend Portfolio That Could Yield 11%+ In 15 Years",
      "id": 135502108,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a195d6cf6f63ff3a582ba0781f7f880d2d995b0baa099181bc58ff07b3fec92f"
    }
  },
  {
    "ts": null,
    "headline": "10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June",
    "summary": "10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June",
    "url": "https://finnhub.io/api/news?id=876cd6e780cc5104c978a8df939dc71739dafda7d1a49f31c54a5968375461bf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750760206,
      "headline": "10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June",
      "id": 135499272,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=876cd6e780cc5104c978a8df939dc71739dafda7d1a49f31c54a5968375461bf"
    }
  },
  {
    "ts": null,
    "headline": "Kinase Inhibitors in Autoimmune Diseases Research Report 2025-2035 | Market Accelerates Amid Rising Disease Prevalence, Kinase Innovation, and Demand for Safer Treatments",
    "summary": "The global kinase inhibitors in autoimmune diseases market is experiencing significant growth, driven by rising autoimmune disease prevalence and advancements in biotechnology, specifically in targeted therapies like JAK inhibitors. These innovations provide a precise approach to treatment, addressing the root causes of immune dysfunction and benefiting from expedited regulatory approvals. While challenges such as high costs and competition persist, heavy investments in research and clinical tri",
    "url": "https://finnhub.io/api/news?id=f89ae81807c5e58d2832df8a100a4f1187de05f6ed3529f1c2ad1d5b248d61d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750756920,
      "headline": "Kinase Inhibitors in Autoimmune Diseases Research Report 2025-2035 | Market Accelerates Amid Rising Disease Prevalence, Kinase Innovation, and Demand for Safer Treatments",
      "id": 135506583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global kinase inhibitors in autoimmune diseases market is experiencing significant growth, driven by rising autoimmune disease prevalence and advancements in biotechnology, specifically in targeted therapies like JAK inhibitors. These innovations provide a precise approach to treatment, addressing the root causes of immune dysfunction and benefiting from expedited regulatory approvals. While challenges such as high costs and competition persist, heavy investments in research and clinical tri",
      "url": "https://finnhub.io/api/news?id=f89ae81807c5e58d2832df8a100a4f1187de05f6ed3529f1c2ad1d5b248d61d9"
    }
  },
  {
    "ts": null,
    "headline": "Bargain Alert: I'm Buying Monthly Dividends Up To 7% Yield",
    "summary": "Discover 2 undervalued monthly dividend stocks with strong growth potential, high credit ratings, and reliable yields.",
    "url": "https://finnhub.io/api/news?id=5a0d85e4a6818dd6f73e9515e59320986d3e575cedb0af5304267710849b74c6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750755600,
      "headline": "Bargain Alert: I'm Buying Monthly Dividends Up To 7% Yield",
      "id": 135497478,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183415939/image_2183415939.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 2 undervalued monthly dividend stocks with strong growth potential, high credit ratings, and reliable yields.",
      "url": "https://finnhub.io/api/news?id=5a0d85e4a6818dd6f73e9515e59320986d3e575cedb0af5304267710849b74c6"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'",
    "summary": "Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are undervalued vs. historical norms.",
    "url": "https://finnhub.io/api/news?id=bcae1d83887a65e6c9f9053eb28696afd7ae4c7b3be1ead657c7a557d5bd0369",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750752000,
      "headline": "2 Dividend Aristocrats Bargains To Buy And 'Never Let Go'",
      "id": 135496728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1652791120/image_1652791120.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are undervalued vs. historical norms.",
      "url": "https://finnhub.io/api/news?id=bcae1d83887a65e6c9f9053eb28696afd7ae4c7b3be1ead657c7a557d5bd0369"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Dividend Backed by Strong Free Cash Flow",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the Best Dividend Leaders to Buy Now. The company’s strategy focuses on steadily increasing its dividend, reinvesting in the business with strong financial returns, and carrying out value-driven share buybacks. In the first quarter, it returned $2.4 billion to shareholders through dividends. Pfizer Inc. (NYSE:PFE)’s cash flow remains strong […]",
    "url": "https://finnhub.io/api/news?id=a099b1617d9584b7f17d39304c6247aae05de53451b6e040272d1c7ecd4b4d39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750734564,
      "headline": "Pfizer’s Dividend Backed by Strong Free Cash Flow",
      "id": 135487533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the Best Dividend Leaders to Buy Now. The company’s strategy focuses on steadily increasing its dividend, reinvesting in the business with strong financial returns, and carrying out value-driven share buybacks. In the first quarter, it returned $2.4 billion to shareholders through dividends. Pfizer Inc. (NYSE:PFE)’s cash flow remains strong […]",
      "url": "https://finnhub.io/api/news?id=a099b1617d9584b7f17d39304c6247aae05de53451b6e040272d1c7ecd4b4d39"
    }
  }
]